IACS-010759 in Advanced Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2/Neu Negative|Metastatic Malignant Solid Neoplasm|Pancreatic Ductal Adenocarcinoma|Progesterone Receptor Negative|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Lymphoma|Refractory Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Solid Neoplasm
Interventions: DRUG: Oxidative Phosphorylation Inhibitor IACS-010759|OTHER: Pharmacodynamic Study|OTHER: Pharmacokinetic Study
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)